Ann: RAP Licenses Additional Pneumonia Diagnostic from UniQuest, page-203

My apologies for the bold writing below copied and pasted from the Rap webpage as I couldnt get the screen shot to load. Anyways looking at paragraph two seems our company see the intergration into a Telehealth's platform in a different light

None the less good to look at it from more than one angle and your discussion has raised a few points that we as shareholders should be excited to be asking in the not to distant future.

I for one am keen to know our plan of attack for taking Rap to commercialisation post trial results/fda approval. I"m sure our management team is already there and looking at what they can control not what they can't (eg trial times/results)

What we do​

ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.​

We will provide telehealth companies with point of care diagnostic solutions that can be easily integrated into their platforms.​

We are working on apps to provide instant clinical quality diagnostic tests and management tools directly to consumers and healthcare providers.​